Sugi Predict

Sugi Predict / Compounds / SCHEMBL3335954

SCHEMBL3335954

SCHEMBL3335954

CCN(O)[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.45
▸ BLM P54132 1/20 0.45
▸ PMP22 Q01453 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ SLC1A2 P43004 3/20 0.32
▸ SLC1A1 P43005 3/20 0.32
▸ SLC1A3 P43003 2/20 0.32
▸ GRIK1 P39086 2/20 0.32
▸ GRIK2 Q13002 2/20 0.32
▸ CHRM1 P11229 1/20 0.31
▸ AKR1A1 P14550 1/20 0.31
▸ CHRM3 P20309 1/20 0.31
▸ HTR2A P28223 1/20 0.31
▸ HTR2C P28335 1/20 0.31
▸ ADRA1A P35348 1/20 0.31
▸ HRH1 P35367 1/20 0.31
▸ DRD3 P35462 1/20 0.31
▸ SLC6A3 Q01959 1/20 0.31
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC2 Q92769 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1221384 1.00 ALOX15 (0.45) ALOX15BLMPMP22KMT2ASLC1A2
D-Glutamate SCHEMBL8219041 0.87 ALOX15 (0.56) ALOX15BLMPMP22KMT2ASLC1A2
SCHEMBL10828944 0.85 KMT2A (0.42) ALOX15BLMPMP22KMT2ASLC1A2
SCHEMBL11659223 0.85 KMT2A (0.42) ALOX15BLMPMP22KMT2ASLC1A2
SCHEMBL7701636 0.84 CYP1A2 (0.45) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL4655463 0.84 CYP1A2 (0.45) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL5988400 0.82 KMT2A (0.47) ALOX15BLMPMP22KMT2ASLC1A2
SCHEMBL2244866 0.82 KMT2A (0.47) ALOX15BLMPMP22KMT2ASLC1A2
SCHEMBL27774327 0.82 KMT2A (0.47) ALOX15BLMPMP22KMT2ASLC1A2
SCHEMBL17772936 0.81 ALOX15 (0.45) ALOX15BLMPMP22KMT2ASLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109293926-B Protease responsive linear-dendritic block copolymer and preparation method and application thereof 云南师范大学 2021-04-23 — — CN claimed
US-20210038732-A1 ANTICANCER MICRORNA AND LIPID FORMULATIONS THEREOF INTERNA TECHNOLOGIES B.V. (NL) 2021-02-11 — — US claimed
EP-3752164-A1 ANTICANCER MICRORNA AND LIPID FORMULATIONS THEREOF InteRNA Technologies B.V. (NL) 2020-12-23 — — EP claimed
CN-111936150-A Anticancer microRNA and lipid preparation thereof 因特尔纳技术有限公司 2020-11-13 — — CN claimed
WO-2019155094-A1 ANTICANCER MICRORNA AND LIPID FORMULATIONS THEREOF INTERNA TECHNOLOGIES B.V. (NL) 2019-08-15 — — WO claimed
US-20100145018-A1 Lipid-Polymer-Conjugates ASTELLAS PHARMA EUROPE BV (NL) 2010-06-10 — — US claimed
US-20050180917-A1 Delivery of neutron capture elements for neutron capture therapy PSIMEI PHARMACEUTICALS PLC (GB) 2005-08-18 — — US claimed
EP-1471939-A1 DELIVERY OF NEUTRON CAPTURE ELEMENTS FOR NEUTRON CAPTURE THERAPY Psimei Pharmaceuticals Plc (GB) 2004-11-03 — — EP claimed
WO-2003055520-A1 DELIVERY OF NEUTRON CAPTURE ELEMENTS FOR NEUTRON CAPTURE THERAPY PSIMEI PHARMACEUTICALS PLC (GB) 2003-07-10 — — WO claimed
US-20260041637-A1 VESICLES BASED ON GLUCOSE-DERIVED SURFACTANTS AND PHYTOSTEROLS NANOMOL TECH S L (ES) 2026-02-12 — — US disclosed
WO-2025242657-A1 LIPOPEPTIDE BUILDING BLOCKS AND AGGREGATES SHAPE BIOPHARMACEUTICALS AG (CH) 2025-11-27 — — WO disclosed
EP-4565208-A1 VESICLES BASED ON GLUCOSE-DERIVED SURFACTANTS AND PHYTOSTEROLS Nanomol Technologies, S.L. (ES) 2025-06-11 — — EP disclosed
WO-2025023195-A1 AGENT FOR TREATMENT OF CANCER, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 国立大学法人 岡山大学 2025-01-30 — — WO disclosed
EP-4430076-A2 POLYMER-INTERACTION MOLECULE CONJUGATES AND METHODS OF USE Life Technologies AS (NO) 2024-09-18 — — EP disclosed
US-6926901-B2 Suberization of a polymeric sustain release matrix for animal repellancy THE CORATO FOUNDATION (US) 2005-08-09 — — US disclosed
US-20040151750-A1 matrix of biopolymers (e.g., a bioerodible polymer and/or a non-absorbable polymer) and repellant chemicals (e.g.,animal repellants such as alkaloids isolated from the family Narcissus) permits sustained release of the chemicals. O' LEARY ROBERT (US) 2004-08-05 — — US disclosed
US-20030202998-A1 Suberization of a polymeric sustain release matrix for animal repellancy CORATO FOUNDATION, THE 2003-10-30 — — US disclosed
US-6565867-B1 Using plant extract toxin THE CORATO FOUNDATION 2003-05-20 — — US disclosed
WO-1991015242-A1 CONJUGATE COMPOUNDS OF POLYMERS WITH OTHER ORGANIC MOLECULAR ENTITIES SCHACHT ETIENNE HONORE (BE) 1991-10-17 — — WO disclosed
EP-0164569-B1 A MEDICINE-RELEASING AGENT KOKEN CO. LTD. (JP) 1990-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100145018-A1 Lipid-Polymer-Conjugates PARG, GLUL, PHOSPHO1 ALOX15 1425/4885BLM 1503/4885PMP22 1935/4885
US-20210038732-A1 ANTICANCER MICRORNA AND LIPID FORMULATIONS THEREOF PLIN3, PLIN5, SREBF2 ALOX15 393/4885BLM 3075/4885PMP22 4220/4885
US-20260041637-A1 VESICLES BASED ON GLUCOSE-DERIVED SURFACTANTS AND PHYTOSTEROLS DDOST, LIPC, PNLIP ALOX15 737/4885BLM 2259/4885PMP22 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.